Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib

NCT06582745 is registered in ClinicalTrials.gov with Cook Children's Health Care System as lead sponsor.

NCT NCT06582745
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06582745 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib
Lead sponsor
Cook Children's Health Care System
Phase
Phase 2
Overall status
Recruiting
Start date
June 24, 2024
Completion date
December 31, 2039
Enrollment
75 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

langerhans cell histiocytosis